Exact Sciences Corporation $EXAS Shares Bought by Integral Health Asset Management LLC

Key Points

• Integral Health Asset Management doubled its stake in Exact Sciences to 200,000 shares in Q3 by buying an additional 100,000 shares, a holding valued at about $10.94 million (≈0.11% of the company).
• Exact Sciences missed on quarterly earnings with EPS of ($0.21) versus a $0.08 consensus, though revenue rose 23.1% year-over-year and the company remains unprofitable (negative net margin; PE -94.15).
• The stock is trading near a 1-year high (~$103.57) with a $19.77 billion market cap and 88.82% institutional ownership, but analysts have largely downgraded the shares to a consensus rating of "Reduce" and a $92.13 target.

Integral Health Asset Management LLC raised its position in Exact Sciences Corporation (NASDAQ:EXAS - Free Report) by 100.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 200,000 shares of the medical research company's stock after purchasing an additional 100,000 shares during the period. Integral Health Asset Management LLC owned about 0.11% of Exact Sciences worth $10,942,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Comerica Bank grew its stake in Exact Sciences by 9.2% in the 3rd quarter. Comerica Bank now owns 1,954 shares of the medical research company's stock valued at $107,000 after acquiring an additional 164 shares during the last quarter. FORA Capital LLC purchased a new stake in Exact Sciences in the 3rd quarter valued at approximately $501,000. Jump Financial LLC purchased a new stake in Exact Sciences in the 3rd quarter valued at approximately $2,849,000. Marshall Wace LLP grew its holdings in Exact Sciences by 32.6% during the 3rd quarter. Marshall Wace LLP now owns 569,637 shares of the medical research company's stock valued at $31,165,000 after buying an additional 139,918 shares during the last quarter. Finally, Entropy Technologies LP boosted its stake in shares of Exact Sciences by 539.8% during the third quarter. Entropy Technologies LP now owns 30,749 shares of the medical research company's stock valued at $1,682,000 after acquiring an additional 25,943 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

Exact Sciences Stock Up 0.3%

Shares of Exact Sciences stock opened at $103.57 on Friday. Exact Sciences Corporation has a 1-year low of $38.81 and a 1-year high of $103.75. The company has a market capitalization of $19.77 billion, a PE ratio of -94.15, a P/E/G ratio of 2.35 and a beta of 1.41. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17. The business has a 50-day moving average of $102.83 and a 200-day moving average of $83.60.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.The firm's revenue was up 23.1% on a year-over-year basis. During the same period last year, the firm posted ($0.06) earnings per share. As a group, equities analysts forecast that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on EXAS. Zacks Research downgraded shares of Exact Sciences from a "strong-buy" rating to a "hold" rating in a research note on Friday, January 30th. Canaccord Genuity Group downgraded Exact Sciences from a "buy" rating to a "hold" rating and increased their target price for the stock from $85.00 to $105.00 in a research report on Tuesday, November 25th. TD Cowen cut Exact Sciences from a "buy" rating to a "hold" rating in a report on Tuesday, November 25th. Jefferies Financial Group lowered shares of Exact Sciences from a "buy" rating to a "hold" rating and upped their price target for the stock from $90.00 to $105.00 in a research report on Monday, November 24th. Finally, BTIG Research lowered shares of Exact Sciences from a "buy" rating to a "neutral" rating in a report on Thursday, November 20th. Twenty-one research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Reduce" and a consensus target price of $92.13.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company's flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.